We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00213798
First Posted: September 21, 2005
Last Update Posted: August 30, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Strasbourg, France
  Purpose
The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool. The aim of this study is to evaluate if plasma DNA can be used as a valuable non invasive test to monitor disease progression without assessing the tumor.

Condition Intervention
Non-Small Cell Lung Carcinoma Small Cell Lung Cancer Procedure: Biopsy samples

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Detection of Plasma DNA by Allelotyping in Non Small Cell and Small Cell Lung Cancer Patients. Evolution During Treatment and Follow-up.

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Estimated Enrollment: 200
Study Start Date: December 2003
Study Completion Date: August 2011
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presence of lung tumor to use fiberoscopy or surgical intervention for diagnosis.
  • No lung instability.
  • Individuals give all informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213798


Locations
France
Service de Pneumologie, Hôpital Lyautey
Strasbourg, France, 67000
Service de Chirurgie Thoracique, Hôpital Civil
Strasbourg, France, 67091
Service de Pneumologie, Hôpital Civil
Strasbourg, France, 67091
Service de Pneumologie, Hôpital de Hautepierre
Strasbourg, France, 67098
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Michèle BEAU-FALLER, MD Service de Pneumologie, Hôpital de Hautepierre
  More Information

Responsible Party: Emmanuel LAVOUE, Directeur Adjoint, University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00213798     History of Changes
Other Study ID Numbers: 2731
First Submitted: September 13, 2005
First Posted: September 21, 2005
Last Update Posted: August 30, 2011
Last Verified: August 2011

Keywords provided by University Hospital, Strasbourg, France:
Lung cancer
plasma DNA
allelotyping
follow-up
Prospective Study
Non-Small Cell Lung Cancer
Small Cell Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms


To Top